CATHOLIC UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION has a total of 29 patent applications. It increased the IP activity by 25.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, medical technology and biotechnology are UNIV MASSACHUSETTS MEDICAL, UNIV NAT CORP TOKYO MEDICAL & DENTAL and CATHOLIC UNIV KOREA INDUSTRY ACADEMIC COOPERATION FOUNDATION.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 18 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 2 | |
#4 | Japan | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Brazil | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Medical technology | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Kim Sung Won | 5 |
#2 | Park Sun Hwa | 4 |
#3 | Lee Hyun Jung | 3 |
#4 | Joo Choun-Ki | 3 |
#5 | Chae Hiun Suk | 3 |
#6 | Chung So-Hyang | 3 |
#7 | Lim Jung Yeon | 3 |
#8 | Yoon Byeong Gon | 2 |
#9 | Seo Kyung Yul | 2 |
#10 | Kim Seok Won | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019022386A2 | Pharmaceutical composition for preventing or treating rheumatoid arthritis including inferior nasal concha-derived mesenchymal stem cell as active ingredient | |
WO2018203651A2 | Human nose inferior nasal concha-derived mesenchymal stem cell-based, 3d bioprinted construct, and use thereof | |
US2016303237A1 | Photodynamic therapy for treating Clostridium difficile infection using chitosan and tetracycline | |
US2016256099A1 | Apparatus and method for measuring thermal conductivity in burns | |
EP3012634A1 | Biomarker for rheumatoid arthritis diagnosis or activity evaluation |